Volume : 12, Issue : 11, November – 2025
Title:
EMERGING INSIGHTS INTO BIOFILM FORMATION AND ITS CONTRIBUTION TO MULTIDRUG RESISTANCE IN PATHOGENIC BACTERIA
Authors :
Nital Adnyan Dandage*,Snehal Yuvaraj Kumbhar, Ajmera siroj Mulani
Abstract :
Bacterial biofilms represent highly organized, surface-associated microbial communities that play a critical role in the persistence and recurrence of infectious diseases. Their complex architecture, dominated by an extracellular polymeric substance (EPS) matrix, provides a protective niche that enables pathogens to survive hostile environmental conditions and evade antimicrobial therapies. Biofilm formation is a dynamic, multistage process regulated by adhesins, surface appendages, quorum sensing networks, and intracellular messengers such as cyclic di-GMP. These regulatory systems, coupled with species-specific mechanisms in Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, and Klebsiella spp., contribute to robust structural integrity and functional adaptability.
The clinical significance of biofilms is highlighted by their involvement in device-associated infections, chronic wounds, cystic fibrosis lungs, urinary tract infections, and endocarditis. Biofilm-embedded cells exhibit remarkable multidrug resistance due to restricted antibiotic penetration, altered metabolic states, persister cell formation, efflux pump activity, horizontal gene transfer, and stress-induced mutational resistance. These features are especially pronounced in high-priority multidrug-resistant pathogens, including ESKAPE organisms, leading to therapeutic failures and prolonged disease burden.
Recent technological advances—such as confocal laser scanning microscopy, electron microscopy, omics-based platforms, microfluidics, and high-throughput biofilm quantification assays—have deepened our understanding of biofilm biology and resistance mechanisms. This review synthesizes emerging insights into biofilm development, molecular regulation, and resistance patterns, while emphasizing the urgent need for innovative strategies to disrupt biofilms and overcome antimicrobial resistance. Understanding these evolving mechanisms is essential for designing targeted therapeutic interventions and improving clinical outcomes in biofilm-associated infections.
KEYWORDS: Biofilm formation; Multidrug resistance; EPS matrix; Quorum sensing; c-di-GMP signaling; Persister cells; Efflux pumps; Horizontal gene transfer; ESKAPE pathogens; Chronic infections; Device-associated infections; Antimicrobial resistance; Advanced microscopy; Omics technologies; Microfluidics.
Cite This Article:
Please cite this article in press Nital Adnyan Dandage et al., Emerging Insights Into Biofilm Formation And Its Contribution To Multidrug Resistance In Pathogenic Bacteria, Indo Am. J. P. Sci, 2025; 12(11).
REFERENCES:
1. Flemming HC, Wingender J. The biofilm matrix. Nat Rev Microbiol. 2010;8(9):623-33.
2. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from natural environment to infectious disease. Nat Rev Microbiol. 2004;2(2):95-108.
3. Donlan RM. Biofilm formation: a clinically relevant microbiological process. Clin Infect Dis. 2001;33(8):1387-92.
4. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284(5418):1318-22.
5. Stewart PS, William Costerton J. Antibiotic resistance of bacteria in biofilms. Lancet. 2001;358(9276):135-8.
6. Davies D. Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov. 2003;2(2):114-22.
7. O’Toole G, Kaplan HB, Kolter R. Biofilm formation as microbial development. Annu Rev Microbiol. 2000;54:49-79.
8. Ryder C, Byrd M, Wozniak DJ. Role of polysaccharides in Pseudomonas aeruginosa biofilm development. Curr Opin Microbiol. 2007;10(6):644-8.
9. Branda SS, Vik A, Friedman L, Kolter R. Biofilms: the matrix revisited. Trends Microbiol. 2005;13(1):20-6.
10. Hobley L, Harkins C, MacPhee CE, Stanley-Wall NR. Giving structure to the biofilm matrix: an overview of individual strategies and emerging themes. FEMS Microbiol Rev. 2015;39(5):649-69.
11. Petrova OE, Sauer K. Sticky situations: key components that control bacterial surface attachment. J Bacteriol. 2012;194(10):2413-25.
12. Dufrêne YF, Persat A. Mechanomicrobiology: how bacteria sense and respond to forces. Nat Rev Microbiol. 2020;18(4):227-40.
13. Jenal U, Reinders A, Lori C. Cyclic di-GMP: second messenger extraordinaire. Nat Rev Microbiol. 2017;15(5):271-84.
14. Valentini M, Filloux A. Biofilms and c-di-GMP signaling: lessons from Pseudomonas aeruginosa. J Bacteriol. 2016;198(1):55-65.
15. Whiteley M, Diggle SP, Greenberg EP. Progress in and promise of bacterial quorum sensing research. Nature. 2017;551(7680):313-20.
16. Li YH, Tian X. Quorum sensing and bacterial social interactions in biofilms. Sensors. 2012;12(3):2519-38.
17. Gao Y, Feng Y. Stress responses in bacteria: how do bacteria deal with environmental challenges? Crit Rev Microbiol. 2020;46(6):731-46.
18. Arciola CR, Campoccia D, Speziale P, Montanaro L, Costerton JW. Biofilm formation in Staphylococcus infections. Clin Microbiol Infect. 2012;18(12):1081-8.
19. Belas R. Biofilms, flagella, and mechanosensing of surfaces by bacteria. Trends Microbiol. 2014;22(9):517-27.
20. Vuong C, Otto M. Staphylococcal biofilms. Microbes Infect. 2002;4(4):481-9.
21. Lewis K. Persister cells, dormancy and infectious disease. Nat Rev Microbiol. 2007;5(1):48-56.
22. Stewart PS. Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol. 2002;292(2):107-13.
23. Zhang L, Mah TF. Involvement of a novel efflux system in biofilm-specific antibiotic resistance in Pseudomonas aeruginosa. J Bacteriol. 2008;190(13):4447-52.
24. Van Acker H, Coenye T. The role of efflux and physiological adaptation in biofilm tolerance and resistance. J Biol Chem. 2016;291(24):12565-72.
25. Flemming HC, Wuertz S. Bacteria and archaea on Earth and their abundance in biofilms. Nat Rev Microbiol. 2019;17(4):247-60.
26. Roberts AP, Mullany P. Horizontal gene transfer in biofilms. Methods Mol Biol. 2011;665:49-65.
27. Normark BH, Normark S. Evolution and spread of antibiotic resistance. J Intern Med. 2002;252(2):91-106.
28. Hall JPJ, Brockhurst MA, Harrison E. Sampling the mobile gene pool: innovation via horizontal gene transfer in bacteria. Philos Trans R Soc Lond B Biol Sci. 2017;372(1735):20160424.
29. Onyango LA, Alreshidi MM. Adaptive responses of Pseudomonas aeruginosa to biofilm microenvironments. Front Microbiol. 2018;9:1968.
30. Penesyan A, Gillings M, Paulsen IT. Antibiotic discovery: combatting bacterial resistance in biofilms by exploring biofilm-specific targets and pathways. Nat Rev Drug Discov. 2023;22(5):351-71.
31. Lebeaux D, Chauhan A, Rendueles O, Beloin C. From in vitro to in vivo models of bacterial biofilm-related infections. Pathogens. 2013;2(2):288-356.
32. Donlan RM, Costerton JW. Biofilms and device-associated infections. Emerg Infect Dis. 2002;8(9):881-90.
33. Leid JG, Shirtliff ME, Costerton JW, Stoodley P. Human leukocytes adhere to, penetrate, and respond to Staphylococcus aureus biofilms. Infect Immun. 2002;70(11):6339-45.
34. Bjarnsholt T. The role of bacterial biofilms in chronic infections. APMIS Suppl. 2013;(136):1-58.
35. Ciofu O, Tolker-Nielsen T. Tolerance and resistance of Pseudomonas aeruginosa biofilms to antimicrobial agents—how P. aeruginosa can escape antibiotics. Front Microbiol. 2019;10:913.
36. Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther. 2013;11(3):297-308.
37. Magill SS, Edwards JR, Bamberg W, et al. Multistate prevalence of healthcare-associated infections. N Engl J Med. 2014;370(13):1198-208.
38. Bordi C, de Bentzmann S. Hacking into host cell–cell communications: a new role for Pseudomonas aeruginosa biofilms. PLoS Pathog. 2011;7(7):e1001299.
39. Gupta P, Sarkar S, Das B, Bhattacharjee S, Tribedi P. Biofilm, pathogenesis and prevention—a journey to break the wall: a review. Arch Microbiol. 2016;198(1):1-15.
40. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74(3):417-33.
41. Besharati F, Saberi R. Microfluidic systems for biofilm studies. Crit Rev Biotechnol. 2021;41(7):1016-34.
42. Azeredo J, Azevedo NF, Briandet R, et al. Critical review on biofilm methods. Crit Rev Microbiol. 2017;43(3):313-51.
43. Stoodley P, Sauer K, Davies DG, Costerton JW. Biofilms as complex differentiated communities. Annu Rev Microbiol. 2002;56:187-209.
44. Lebeaux D, Ghigo JM, Beloin C. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of biofilm formation. Clin Microbiol Rev. 2014;27(3):637-57.
45. Vishal R. Rasve, Vivek V. Paithankar, Mrunal K. Shirsat, Avinash V. Dhobale, “Evaluation of Antiulcer Activity of Aconitum Heterophyllum on Experimental Animal” World Journal of Pharmacy and Pharmaceutical sciences 2018; volume 7 issue 2. Page no. 819-839.
46. Koo H, Allan RN, Howlin RP, Stoodley P, Hall-Stoodley L. Targeting microbial biofilms: current and prospective therapeutic strategies. Nat Rev Microbiol. 2017;15(12):740-55.
47. Arciola CR, Montanaro L, Costerton JW. New trends in diagnosis and control strategies for implant infections. Int J Artif Organs. 2011;34(9):771-6.
48. Oliveira NM, Martinez-Garcia E, Xavier J. Multilevel selection enables the evolution of cooperation in microbial biofilms. Nat Commun. 2019;10:2213.
49. Toyofuku M, Nomura N, Eberl L. Types and origins of extracellular vesicles in bacteria. Curr Opin Microbiol. 2019;45:16-22.
50. Karygianni L, Ren Z, Koo H, Thurnheer T. Biofilm matrixome: extracellular components in structured microbial communities. Trends Microbiol. 2020;28(8):668-81.
51. Lewis K. The science of antibiotic discovery. Cell. 2020;181(1):29-45.